Fmr LLC Has $1.11 Billion Holdings in Haleon plc (NYSE:HLN)

Fmr LLC lifted its holdings in shares of Haleon plc (NYSE:HLN) by 5.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,918,269 shares of the company’s stock after buying an additional 5,768,117 shares during the quarter. Fmr LLC owned about 2.32% of Haleon worth $1,110,035,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Sculptor Capital LP boosted its holdings in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after buying an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC grew its holdings in Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company increased its stake in Haleon by 95.5% in the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after purchasing an additional 954,622 shares in the last quarter. Natixis Advisors LLC raised its holdings in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares during the period. Finally, Raymond James & Associates boosted its position in shares of Haleon by 14.7% during the second quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock worth $33,205,000 after purchasing an additional 515,651 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Berenberg Bank began coverage on Haleon in a research note on Tuesday, August 6th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Stock Performance

HLN opened at $9.73 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market capitalization of $44.02 billion, a price-to-earnings ratio of 28.60, a P/E/G ratio of 2.89 and a beta of 0.30. The business’s 50-day moving average price is $9.97 and its two-hundred day moving average price is $9.41. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.